CARBIOS
24.6.2021 07:02:13 CEST | Business Wire | Press release
The promise of endlessly recycled PET plastic is one step closer today, as the Consortium – Carbios, L’Oréal, Nestlé Waters, PepsiCo and Suntory Beverage & Food Europe – announces the successful production of the world’s first food-grade PET plastic bottles produced entirely from enzymatically recycled plastic.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210623005867/en/
Each Consortium company has successfully manufactured sample bottles – based on Carbios’ enzymatic PET recycling technology – for some of their leading products including: Biotherm®, Perrier®, Pepsi Max®** and Orangina®.
Today’s announcement is the culmination of nearly 10 years’ research and development by Carbios to create a new process and supercharge an enzyme naturally occurring in compost heaps that normally breaks down leaf membranes of dead plants. By adapting this enzyme, Carbios has fine-tuned the technology and optimized this enzyme to break down any kind of PET plastic (regardless of color or complexity) into its building blocks, which can then be turned back into like-new, virgin-quality plastic.
Carbios’ patented enzymatic PET recycling process enables a wide variety of PET plastics to be recycled into virgin quality, food grade rPET. PET plastics that would otherwise go to waste or be incinerated, can now be brought back into a continuous circular system of recycling. And this can be achieved at high speed – breaking down 97% of plastic in just 16 hours – 10,000 times more efficient than any biological plastic recycling trial to date (peer-reviewed article in Nature ).
Together, these brands will work to scale this innovation to help meet the global demand for sustainable packaging solutions. In September 2021, Carbios will break ground on a demonstration plant, before launching a 40,000 tons capacity industrial facility, by 2025.
Commenting on the announcement, Carbios’ CEO Jean Claude Lumaret commented: “In a world first, we have created food-grade clear bottles from enzymatically recycled colored and complex plastic with identical properties to virgin PET, and in partnership with the Consortium, we have proved the viability of the technology with the world’s leading brands. This is a truly transformational innovation that could finally fully close the loop on PET plastic supply globally, so that it never becomes waste.”
Jacques Playe, L’Oréal’s Global Head of Packaging and Product Development added: “We have been working with Carbios since 2017 to develop this first bottle made from PET derived from enzymatic recycling technology, an alternative to mechanical recycling. We are pleased to announce today the feasibility of these bottles in a pilot phase and are delighted to be in a position to create the packaging of the future with our partners. This is a promising innovation for the years to come that demonstrates our commitment to bring to market more environmentally friendly packaging and which is part of a circularity initiative begun more than 15 years ago”.
Jean-Francois Briois, Head of Packaging Material Science and Environmental Sustainability Nestlé Waters global R&D added: “It is very exciting to see that the quality of the prototype bottles made from colored recycled PET materials is virtually identical to clear virgin PET. When we reach industrial scale, this enzymatic recycling technology will enable us to produce high-quality rPET bottles and help Nestlé Waters in our journey to boost the circular economy and reduce the use of virgin plastics.”
Ron Khan, Global VP of Packaging, Beverages, PepsiCo added: “PepsiCo is committed to building a circular economy to achieve our vision that packaging never becomes waste. We are dedicated to reducing the virgin plastic we use and with the breakthrough Carbios enzymatic recycling technology, we can help keep valuable material in the circular economy, reduce waste and take another step toward a truly closed loop system.”
Roberto Vanin, Chief R&D Officer, Suntory Beverage & Food Europe, added: “The global issue of plastic waste requires transformational thinking, creative partnerships and innovative brands coming together to seek out new solutions. Continued investment in new ways of tackling waste and creating true circularity such as this ground-breaking technology from Carbios will be key to Suntory Beverage & Food Europe achieving its 100% sustainable plastic ambition.”
Enzymatic recycling overcomes the issue of degradation in conventional recycling and can be used on any type of PET plastic. Because Carbios’ recycling process works under mild conditions, it could also lower the carbon footprint of PET waste treatment by saving 30% of CO2 emissions compared to a conventional end of life mix of incineration and landfill, taking virgin PET production substitution into account.***
The successful completion of these initial food-grade bottles is a major milestone in the Consortium’s validation of Carbios’ technology. This partnership is part of a growing trend amongst brands to collaborate across industries to tackle these global challenges, working towards a world of circularity, where we limit the production of virgin plastic.
Carbios will license its technology to PET manufacturers worldwide, accelerating the global adoption of enzymatic recycling for all kinds of PET based products.
Notes to Editors
To book interviews or to request further information or images, please contact lon-carbios@ketchum.com
** Pepsi Max® also known as Pepsi Black or Pepsi Zero Sugar in other global markets.
*** Preliminary Life Cycle Assessment of Carbios PET recycling process, 2021
About Enzymatic Recycling
Around 70 million tons of PET plastic is manufactured globally every year – equal to around 20% of all plastic – but through repeated conventional thermomechanical processes, the plastic used in packaging is degraded over time and requires new virgin plastic to retain its quality.
Carbios has successfully hyper-charged a naturally occurring enzyme from compost heaps that breaks down leaf membranes of dead plants. PET plastic is made from a string of building blocks also called monomers and this optimized enzyme is super-efficient at cutting the PET plastic into these building blocks: terephthalic acid and ethylene glycol. Those monomers can then be recombined to recreate the PET polymer, at food grade quality, in an infinite, virgin-quality loop.
About Carbios
Carbios, a green biotech company, develops biological and innovative processes to revolutionize the end of life of plastics and textiles. Through its unique approach of combining enzymes and plastics, Carbios aims to address new consumer expectations and the challenges of a broader energy transition by taking up a major challenge of our time: plastic and textile pollution. Carbios was named one of the World Economic Forum’s Technology Pioneers of 2021 .
Carbios and L’Oréal founded the Consortium in 2017 and were joined in 2019 by Nestlé Waters, PepsiCo and Suntory Beverage & Food Europe.
For more information, please visit http://www.carbios.com/en/
For more information, please visit:
https://www.suntorybeverageandfood-europe.com
https://www.linkedin.com/company/suntory-beverage-&-food-europe-limited/
View source version on businesswire.com: https://www.businesswire.com/news/home/20210623005867/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
